Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in Refractory SLE
NCT05930314Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of inaticabtagene autoleucel in systemic lupus erythematosus (SLE), lupus nephritis (LN) and immune thrombocytopenia (ITP), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
inaticabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05930314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930314.